ストックスクリーナーアプリを入手
67.99
2.58%
-2.03
前日終値:
$70.02
開ける：
$69.12
24時間の取引高:
117.25K
Relative Volume:
0.06
時価総額：
$8.03B
収益：
$947.36M
当期純損益:
$392.47M
株価収益率:
22.51
EPS:
3.02
ネットキャッシュフロー:
$392.71M
1週間 パフォーマンス:
-1.46%
1か月 パフォーマンス:
-13.02%
6か月 パフォーマンス:
-8.97%
1年 パフォーマンス:
+14.58%
1日の値動き範囲:
$67.88
$69.51
1週間の範囲:
$68.02
$71.53
52週間の値動き範囲:
$47.50
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
名前
Halozyme Therapeutics Inc
セクター
電話
(858) 794-8889
住所
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
68.07 | 8.26B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.29 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.18 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
730.02 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.68 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.05 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-04 | ダウングレード | Goldman | Neutral → Sell |
| 2025-10-14 | アップグレード | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 再開されました | Goldman | Neutral |
| 2025-05-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | ダウングレード | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-06-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 開始されました | TD Cowen | Outperform |
| 2023-07-24 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-24 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-10 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 再開されました | Berenberg | Buy |
| 2023-03-16 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 再開されました | Morgan Stanley | Overweight |
| 2022-11-28 | 開始されました | Wells Fargo | Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | 開始されました | Evercore ISI | Outperform |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 繰り返されました | The Benchmark Company | Buy |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-07-01 | 開始されました | The Benchmark Company | Buy |
| 2020-02-05 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 開始されました | Goldman | Buy |
| 2019-11-05 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 再開されました | Piper Jaffray | Neutral |
| 2018-05-11 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 開始されました | Goldman | Neutral |
| 2017-10-16 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-01-06 | ダウングレード | Citigroup | Buy → Neutral |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-11-18 | 開始されました | Citigroup | Buy |
| 2015-09-22 | 開始されました | Barclays | Overweight |
| 2015-06-22 | 繰り返されました | JP Morgan | Overweight |
| 2015-03-03 | 繰り返されました | UBS | Buy |
| 2015-02-18 | 繰り返されました | MLV & Co | Buy |
| 2015-01-08 | 繰り返されました | MLV & Co | Buy |
すべてを表示
Halozyme Therapeutics Inc (HALO) 最新ニュース
Halozyme Therapeutics, Inc. $HALO Shares Sold by GW&K Investment Management LLC - MarketBeat
Cresset Asset Management LLC Reduces Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Did Record ENHANZE Royalties and New Deals Just Shift Halozyme Therapeutics' (HALO) Investment Narrative? - simplywall.st
Is Halozyme Therapeutics (HALO) Pricing Reflect Long Term Prospects After Recent Share Pullback - Yahoo Finance
Halozyme Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics - Markets Mojo
Halozyme Therapeutics (HALO) Valuation Check As Recent Share Pullback Follows Strong Multi Year Returns - Yahoo Finance
Segall Bryant & Hamill LLC Sells 94,261 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Fisher Asset Management Boosts Stake in Halozyme Therapeutics - National Today
Fisher Asset Management LLC Purchases 29,147 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALO Earnings History & Surprises | EPS & Revenue Results | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme at TD Cowen Health Care Conference: Strategic Growth Insights - Investing.com
Halozyme Therapeutics (HAM:RV7) Total Operating Expense : €318 Mil (TTM As of Dec. 2025) - GuruFocus
Halozyme Therapeutics Sees Increased Investment from Handelsbanken Fonder AB - National Today
Halozyme Therapeutics Stock Holdings Reduced by Rafferty Asset Management - National Today
Halozyme Therapeutics, Inc. $HALO Stock Holdings Lessened by Rafferty Asset Management LLC - MarketBeat
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unlocking A 21.53% Potential Upside - DirectorsTalk Interviews
Halozyme Therapeutics (HAM:RV7) Ending Cash Position : €117 Mil (As of Dec. 2025) - GuruFocus
Why Halozyme Therapeutics (HALO) Is Up 8.1% After Raising 2026 Revenue Guidance to up to $1.81 Billion - Sahm
Halozyme Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
A Look At Halozyme Therapeutics (HALO) Valuation After Recent Share Price And Licensing Momentum - simplywall.st
Is Halozyme Therapeutics (HALO) a Buy Post Earnings? - Finviz
Artisan Partners Limited Partnership Sells 752,150 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HAM:RV7) Preferred Stock : €0 Mil (As of Dec. 2025) - GuruFocus
12 Cheap Biotech Stocks to Buy Now - Insider Monkey
Halozyme Therapeutics, Inc. (HALO): A Bull Case Theory - Finviz
Halozyme Therapeutics (HAM:RV7) Book Value per Share : €0.35 (As of Dec. 2025) - GuruFocus
Halozyme Therapeutics, Inc. $HALO Position Boosted by Handelsbanken Fonder AB - MarketBeat
Halozyme Therapeutics (HAM:RV7) Additional Paid-In Capital : €10 Mil(As of Dec. 2025) - GuruFocus
Halozyme Therapeutics (HAM:RV7) ROE % Adjusted to Book Value : -1.24% (As of Dec. 2025) - GuruFocus
Halozyme Therapeutics, Inc. $HALO Shares Sold by Cary Street Partners Financial LLC - MarketBeat
Halozyme Therapeutics (HAM:RV7) Revenue : €1,215 Mil (TTM As of Dec. 2025) - GuruFocus
HALO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Halozyme Therapeutics (HAM:RV7) Non Operating Income : €-271 Mil (TTM As of Dec. 2025) - GuruFocus
Halozyme Therapeutics (HAM:RV7) Sloan Ratio % : 8.55% (As of Dec. 2025) - GuruFocus
Halozyme Therapeutics (HAM:RV7) Accumulated Depreciation : €-28 Mil (As of Dec. 2025) - GuruFocus
Halozyme Therapeutics Inc (HAM:RV7) Stock Price, Trades & News - GuruFocus
Intech Investment Management LLC Increases Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HAM:RV7) Sale Of Property, Plant, Eq - GuruFocus
Halozyme Therapeutics (HAM:RV7) PS Ratio : 6.05 (As of Feb. 27, 2026) - GuruFocus
Halozyme Therapeutics (HAM:RV7) 14-Day RSI : 39.66 (As of Feb. 27, 2026) - GuruFocus
Halozyme Therapeutics (HAM:RV7) ROIC % : 50.61% (As of Dec. 2025) - GuruFocus
TD Asset Management Inc Has $75.92 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HAM:RV7) Tangible Book per Share - GuruFocus
Halozyme Therapeutics (HAM:RV7) Property, Plant and Equipme - GuruFocus
Halozyme Therapeutics (HAM:RV7) Gross Property, Plant and E - GuruFocus
Halozyme Therapeutics (HAM:RV7) EV-to-OCF : 15.15 (As of Feb. 27, 2026) - GuruFocus
Halozyme Therapeutics (HAM:RV7) Payments of Debt : €0 Mil (TTM As of Dec. 2025) - GuruFocus
Halozyme Therapeutics (HAM:RV7) Net Income (Discontinued Op - GuruFocus
Halozyme Therapeutics (HAM:RV7) Preferred Dividends : €0 Mil (TTM As of Dec. 2025) - GuruFocus
Halozyme Therapeutics (HAM:RV7) Other Noninterest Expense - GuruFocus
Halozyme Therapeutics (HAM:RV7) Sale Of Investment : €622 Mil (TTM As of Dec. 2025) - GuruFocus
Halozyme Therapeutics Inc (HALO) 財務データ
収益
当期純利益
現金流量
EPS
Halozyme Therapeutics Inc (HALO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Mar 03 '26 |
Option Exercise |
12.07 |
20,000 |
241,400 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
Mar 04 '26 |
Option Exercise |
12.07 |
10,000 |
120,700 |
777,780 |
| Torley Helen | PRESIDENT AND CEO |
Mar 02 '26 |
Sale |
69.69 |
20,000 |
1,393,894 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Mar 03 '26 |
Sale |
69.01 |
20,000 |
1,380,149 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Mar 04 '26 |
Sale |
70.21 |
10,000 |
702,114 |
767,780 |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER |
Feb 20 '26 |
Option Exercise |
0.00 |
2,666 |
0 |
15,403 |
| Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER |
Feb 23 '26 |
Option Exercise |
0.00 |
7,011 |
0 |
51,392 |
| Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER |
Feb 20 '26 |
Option Exercise |
0.00 |
5,332 |
0 |
47,257 |
| LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER |
Feb 23 '26 |
Option Exercise |
0.00 |
6,688 |
0 |
42,102 |
| LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER |
Feb 20 '26 |
Option Exercise |
0.00 |
5,332 |
0 |
38,290 |
0.50%
大文字化:
|
ボリューム (24 時間):